The PIVIE Oversight Problem
Unlike CLABSIs, CAUTIs, or pressure injuries, there is no governing body mandating standardized reporting, tracking, or benchmarking for PIVIEs. No national definitions. No universal metrics. No financial penalties tied to outcomes.
If a PIVIE causes severe tissue injury, blistering, necrosis, or the need for surgical intervention, it may be documented—but it may never make it onto a quality dashboard. It may never be compared year over year. And it may never trigger a systemic response.
What isn’t measured isn’t managed. And what isn’t managed quietly continues.
The Unintended Consequence of CLABSI Reduction
Hospitals Are On Their Own.
Without external mandates, hospitals are left to individually decide:
- What constitutes a reportable PIVIE
- How to document severity
- Whether trends are reviewed
- And what level of injury is considered “acceptable”
That variability leaves facilities exposed. It leaves clinicians unsupported. And it leaves patients vulnerable to preventable harm.
Yes, PIVIEs Will Happen. Severe Harm Doesn’t Have To.
Let’s be clear: infiltrations and extravasations will happen, even in incredibly skilled hands. Peripheral IV therapy is not risk-free, but the most devastating outcomes—deep tissue injury, necrosis, long-term impairment—are not inevitable. They are the result of late detection.
By the time swelling and skin changes are visible, the damage is already done.
Early detection changes everything.
From Silent Harm to Visible Prevention
IV surveillance technology provides something policies and antidotes alone cannot: time.
Time to detect a problem before tissue injury occurs.
Time to intervene early, when a simple antidote may be sufficient.
Time to prevent serious harm rather than respond to it.
Until PIVIEs are systematically tracked and addressed with the same accountability applied to other hospital-acquired conditions, they will continue to cause preventable harm outside formal oversight.